Study of the effect of Parijata leaves extract comparison to Agnikarma in Gridhrasi w.s.r. to Sciatica

A Randomized clinical trial to evaluate the effect of Parijata leaves extract in comparison to Agnikarma in Gridhrasi w.s.r. to Sciatica

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/07/035232

Enrollment

Registered

2021-07-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M50-M54- Other dorsopathies Health Condition 2: M543- Sciatica Health Condition 3: M543- Sciatica

Interventions

Intervention1: Group-B: Trial Drug(Parijata extract capsule): 15 Patients will be treated with oral administration of Parijata Leaves Extract capsule Dose- 1 capsule(500mg) BD Route of administration-

Eligibility

Inclusion criteria

Inclusion criteria: Typical Feature of Gridhrasi Present according to Samhita Patients with positive SLR test and Braggard test Sciatica due to disc prolapsed

Exclusion criteria

Exclusion criteria: Patients with uncontrolled Diabetes mellitus and Hypertension, Cardiovascular disease, Endocrinal disorders HIV, Hepatitis positive Patients Patients with local infection or Skin disease on the site of Agnikarma

Design outcomes

Primary

Measure	Time frame
Reduced the Symptoms of Gridhrasi(Sciatica)Timepoint: 4 weeks	—

Secondary

Measure	Time frame
Patients reported quality of life Gridhrasi related pain intensity and duration Length of hospital stay Time for Patient to resume normal activitiesTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr Manorma Singh

National Institute of Ayurveda, Jaipur

sumanhp2006@gmail.com9418159666

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026